Efficacy and Tolerability of Triple‐Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: A Subgroup Analysis of Patients Stratified by Hypertension Severity, Age, Sex, and Obesity. Issue 10 (20th September 2014)

• Record Type: Journal Article
• Authors: Kreutz, Reinhold; Ammentorp, Bettina; Laeis, Petra; de la Sierra, Alejandro
• Is Part Of: Journal of clinical hypertension. Volume 16:Issue 10(2014:Oct.)
• Page Start: 729
• Page End: 740
• Publication Date: 2014-09-20
• Subjects: Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.12408
• Languages: English
• ISSNs: 1524-6175

Abstract

<abstract abstract-type="main" id="jch12408-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity. A total of 2690 patients, aged 18 years and older, with seated blood pressure (SeBP) ≥160/100 mm Hg received placebo or OLM/AML 20/5 mg, 40/5 mg, or 40/10 mg during a 2‐week, double‐blind, run‐in period, after which they were allocated to one of eight treatment groups with the same OLM/AML dose or with HCTZ 12.5 mg or 25 mg added for 8 weeks. By week 10, greater reductions in SeBP were observed in each OLM/AML/HCTZ group (<italic>P</italic>&lt;.05, respectively) compared with the corresponding dual dose. Adding HCTZ increased blood pressure–lowering efficacy in all subgroups, with a higher proportion of blood pressure goal achievement vs dual therapy. OLM/AML/HCTZ reduced SeBP to a greater extent than OLM/AML in patients with moderate to severe hypertensive; this was unaffected by baseline hypertension severity, age, sex, and obesity.</p> </abstract>